U.S. Marine and Shipping Stock News

Stoke Therapeutics (STOK) has reported FY 2025 results that feature a wide range of quarterly outcomes. Q1 revenue was US$158.6 million with EPS of US$1.95, followed by Q2 revenue of US$13.8 million and an EPS loss of US$0.40, and Q3 revenue of US$10.6 million with an EPS loss of US$0.65. Over recent periods the company has seen revenue move between US$4.8 million and US$158.6 million per quarter, while EPS has shifted from a US$2.07 loss in FY 2024 to a US$1.95 profit and then back into...

WW International (WW) has just posted its FY 2025 results with Q3 revenue of US$172.1 million and a basic EPS loss of US$1.04, set against a trailing 12 month net income of about US$1.1 billion that reflects a large one off gain. Over recent quarters the company has seen revenue move between US$184.4 million and US$202.1 million, while EPS has swung from a profit of US$0.31 to a loss of US$0.91 and then a very large profit of US$15.71. This pattern points to margins that appear to be heavily...

Doximity (DOCS) is back in focus after releasing a new report showing that 94% of U.S. physicians are using or considering artificial intelligence tools in clinical practice, with broad applications across clinical and administrative tasks. See our latest analysis for Doximity. Despite the excitement around its AI report, Doximity’s share price tells a different story, with a 1 day share price return of 1.30%, a 90 day share price return showing a 43.01% decline, and a 1 year total...

SEALSQ (LAES) has agreed to raise about US$125 million through a registered direct offering of ordinary shares and warrants. The funding move is aimed at liquidity and the commercial rollout of its post quantum and quantum technologies. See our latest analysis for SEALSQ. The follow on offering headlines a busy month for SEALSQ, which also outlined new quantum resilient security products and extended its collaboration with Parrot. However, the share price performance has been weak, with a 7...

If you are wondering whether Babcock & Wilcox Enterprises at around US$14.90 still offers value or if the opportunity has passed, the key is to look closely at what the current price really implies. The stock has recorded a 6.1% return over the past week, 52.8% over the last 30 days and 134.6% year to date, with a very large 1 year return figure that may have shifted how the market views its risk and reward profile. Recent headlines have focused on Babcock & Wilcox Enterprises as part of...

Stagwell (STGW) has put a fresh financing option on the table, filing a US$125.4 million shelf registration for up to 20,000,000 Class A shares tied to an ESOP related offering. See our latest analysis for Stagwell. That shelf filing comes shortly after Stagwell reported fourth quarter and full year 2025 results and completed a sizable buyback program. The stock has gained a 23.1% 30 day share price return to US$6.07, even though the 1 year total shareholder return is roughly flat and the 3...

In recent days, Accenture completed the acquisition of UK-based AI firm Faculty, expanded partnerships with Databricks and Google Cloud, joined a new Torus defence supply chain alliance, and was named the Official Business and Technology Consulting Partner of The R&A through 2031. Together these moves deepen Accenture’s AI and data capabilities across sectors from retail to defence and sport, while concentrating technical leadership in its new chief technology officer, Faculty co-founder Dr...

Alibaba Group Holding (NYSE:BABA) has reorganized its AI operations around a new enterprise-focused unit called Alibaba Token Hub. The company is rolling out agentic AI platforms for businesses, including a new system called Wukong, and plans to plug these agents into services such as Taobao and Alipay. This realignment is being driven by CEO Eddie Wu as Alibaba looks to coordinate its AI products and pursue new monetization opportunities across its ecosystem. Alibaba Group Holding now...

Understanding nCino after a prolonged share price slide nCino (NCNO) has seen its share price weaken over the past year, with negative returns over the past month, past 3 months, and year, putting its current US$15.23 level in focus for valuation minded investors. See our latest analysis for nCino. The recent 40.0% three-month share price decline and 38.2% year-to-date share price return reflect fading momentum, while the 46.6% one-year total shareholder return loss highlights how prolonged...

Capital One Financial (COF) is in focus after a proposed class action settlement on its 360 Savings accounts and fresh commentary from management on integrating Discover Financial and Brex within a digital-first growth plan. See our latest analysis for Capital One Financial. Despite the legal settlement headlines and management’s confidence around integrating Discover and Brex, the share price has slipped recently. The 30-day share price return is 11.55% and the 90-day share price return is...

Morgan Stanley (MS) recently limited investor withdrawals from its North Haven Private Income Fund, honoring 45.8% of redemption requests. This move spotlights liquidity pressures in private credit funds during periods of heavier outflows. See our latest analysis for Morgan Stanley. Recent gating of the North Haven Private Income Fund comes as Morgan Stanley’s share price, last closing at US$157.83, posts a 1 day share price return of 1.37% alongside a 30 day share price return of 7.78% and a...

Earlier this week, Savers Value Village reported preliminary fourth-quarter results showing an 8.8% rise in U.S. comparable sales and 0.7% growth in Canada, while President and COO Jubran N. Tanious exercised options for 100,000 shares at US$1.41 and sold 45,000 shares for about US$373,644 on March 11, 2026. This combination of stronger U.S. store performance and fresh insider share activity offers investors new information on both operational momentum and executive incentives. We’ll now...

Q3 2026 snapshot: Value Line (VALU) leans on margins as earnings trends soften Value Line (VALU) has just reported its Q3 2026 results, with recent quarters showing revenue around US$8.6 million and basic EPS between US$0.42 and US$0.69, while trailing twelve month EPS sits a little above US$2.25. Over the last six reported quarters, revenue has ranged from US$8.39 million to US$8.97 million and basic EPS has moved between US$0.42 and US$0.69, setting up a picture where high profitability...

Coya Therapeutics (COYA) has released its FY 2025 results, reporting fourth quarter revenue of US$4.0 million and a basic EPS loss of US$0.34, alongside trailing twelve month revenue of US$7.9 million and a basic EPS loss of US$1.27. The company’s revenue increased from US$0.00 million in the third quarter of 2024 to US$3.6 million in the third quarter of 2025, while quarterly basic EPS has ranged from a loss of US$0.44 in the first quarter of 2025 to a loss of US$0.13 in the third quarter of...

Zomedica (OTCPK:ZOMD.F) has reported its FY 2025 third quarter with total revenue of US$8.1 million and a basic EPS loss of US$0.006, alongside a net loss of US$6.1 million. Over recent quarters, revenue has moved from US$6.1 million in Q2 2024 to US$6.5 million in Q1 2025 and US$8.1 million in Q3 2025, while quarterly net losses have ranged from US$6.1 million to US$63.8 million and trailing twelve month revenue has reached US$29.5 million against a trailing net loss of US$84.5 million. For...

BlackRock (NYSE:BLK) limited withdrawals from its HPS Corporate Lending Fund (HLEND) for the first time, capping redemptions at 5% of total shares. The move comes as HLEND faces rising redemption pressure in a challenging private credit environment. A securities fraud investigation has been opened into whether BlackRock and certain officers engaged in unlawful business practices. Similar withdrawal restrictions at other private credit managers point to broader funding and liquidity stress...

Consolidated Water (CWCO) has put up another solid top line in FY 2025 so far, with Q3 revenue of about US$35.1 million and basic EPS of roughly US$0.35, while the latest trailing twelve months show revenue of about US$130.8 million and EPS of around US$1.09. Over recent periods the company has seen revenue move from roughly US$28.4 million in Q4 2024 to US$35.1 million in Q3 2025, with quarterly EPS shifting from about US$0.11 to US$0.35 over the same stretch. This sets up a story where...

In March 2026, Broadcom announced a suite of AI-focused networking and optical products, including its 3nm Taurus 400G/lane optical DSP and Tomahawk 6 switches, while also joining new industry groups such as the 400G Optical MSA and OCI MSA to define next‑generation, interoperable optical interfaces for large‑scale AI data centers. These launches and alliances show Broadcom moving beyond individual chips toward an integrated AI infrastructure stack, spanning compute, networking, optics, and...

Zymeworks (ZYME) is back in focus after announcing that one oral presentation and six abstracts from its proprietary antibody drug conjugate pipeline were accepted for the 2026 American Association for Cancer Research Annual Meeting. See our latest analysis for Zymeworks. The AACR update comes as the share price sits at US$24.04, with a 30 day share price return of 6.37%, a year to date share price return of 9.69%, and a 1 year total shareholder return of 94.81%. This suggests strong longer...

AXT (NasdaqGS:AXTI) reported material insider stock sales by its CEO and a director, alongside an update to revenue guidance. The company lowered revenue expectations after facing reduced export permits for indium phosphide from China. Management continues to emphasize expansion plans and a highly optimistic outlook despite these regulatory and operational challenges. These developments come as AXT trades at $44.36, with the stock showing very large gains of 2,464.2% over the past year and...

Apple (AAPL) continues to attract investor attention as a mega cap tech name, with the share price recently closing at US$254.23 and a 1 year total return of about 20%. See our latest analysis for Apple. Recent trading has been softer, with a 7 day share price return showing a 2.53% decline and a 90 day share price return showing a 6.48% decline, even as the 1 year total shareholder return is 20.05%. This suggests near term momentum has cooled while longer term performance remains...

MongoDB (NasdaqGM:MDB) has filed a $1.35b shelf registration for Class A Common Stock. The filing allows the company to issue shares over time to support corporate initiatives and potential ESOP related actions. The move introduces the possibility of a higher future share count, which may be relevant for existing and prospective shareholders. MongoDB enters this filing period with a share price of $272.27 and a mixed recent return profile. The stock is up 0.6% over the past week and 44.3%...

The FDA approved an updated label for Krystal Biotech's Vyjuvek (beremagene geperpavec svdt) for epidermolysis bullosa. KB803 progressed as an emerging therapy candidate in Krystal Biotech's pipeline. These developments affect the treatment options available for epidermolysis bullosa and the outlook for NasdaqGS:KRYS. Krystal Biotech, listed on NasdaqGS:KRYS, focuses on gene therapies for rare skin conditions such as epidermolysis bullosa. With Vyjuvek already in the market and KB803 moving...

AngloGold Ashanti (NYSE:AU) completed its acquisition of Centamin in late 2024, bringing the Sukari mine into its portfolio. The Sukari mine produced 500,000 ounces of gold in 2025 and has been classified as a Tier 1 asset within the group. The company also completed its migration to a global domicile, with a primary NYSE listing and headquarters in London. For investors watching NYSE:AU, these changes follow a share price of $96.2 and a 12.4% gain year to date, with a very large return...